A short time-to-treatment was observed in Cluster 2 patients compared to Cluster 1 patients (p = 0.01) (Fig. 5F), demonstrating that expression of IL10-, TGFβ1- and FOXP3 in CLL B cells may predict disease progression in CLL patients. Here, TGFB1 is linked to B-cell chronic lymphocytic leukemia.